Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for Methylphenidate Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 7, 2026, 7:29 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

NCT03772834
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Exercise Intervention, Methylphenidate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Stretching
Behavioral · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate and a Nursing Telephone Intervention for Fatigue

NCT00424099
View directory record Official record
Conditions
Advanced Cancer, Fatigue
Interventions
Methylphenidate, Nursing Telephone Intervention, Placebo, Non NTI
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 7, 2026, 7:29 PM EDT
Active, not recruiting Phase 4 Interventional

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

NCT05469386
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate to Improve Balance and Walking in MS

NCT01896700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Apathy in Dementia Methylphenidate Trial 2

NCT02346201
View directory record Official record
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

NCT01533493
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions
Placebo, Memantine Hydrochloride, OROS-Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 7, 2026, 7:29 PM EDT
Terminated Not applicable Interventional Results available

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01100658
View directory record Official record
Conditions
ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute, L1, Lymphoblastic Leukemia, Acute, L2, Lymphoblastic Lymphoma, Lymphocytic Leukemia, Acute, Lymphocytic Leukemia, L1, Lymphocytic Leukemia, L2, Brain Tumors, Cancer of the Brain, Cancer of Brain, Malignant Primary Brain Tumors, Brain Neoplasms, Malignant
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 7, 2026, 7:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

NCT03525873
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Methylphenidate, Physical Activity, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 7, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02148783
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 7, 2026, 7:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

NCT01628029
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
Interventions
Counseling, Methylphenidate Hydrochloride, Phototherapy, Placebo Administration, Quality-of-Life Assessment, Sham Intervention, Therapeutic Melatonin
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 7:29 PM EDT
Recruiting Phase 4 Interventional

Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

NCT05776056
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 7, 2026, 7:29 PM EDT
Active, not recruiting Phase 2 Interventional

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

NCT01410942
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 7, 2026, 7:29 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

NCT03610282
View directory record Official record
Conditions
Anesthesia
Interventions
IV Methylphenidate, Propofol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

NCT00495820
View directory record Official record
Conditions
Alzheimer's Disease, Apathy, Dementia
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 4 Interventional

A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

NCT00181571
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 7, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 7, 2026, 7:29 PM EDT